Search
for
Sort by
Research 571–600 of 914
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Study of vitamin D deficiency in patients with alopecia areata attending a dermatology center in Iran
- Why Do Not All Chemotherapy Patients Lose Their Hair? Answering an Intriguing Question
- Trichoscopic Findings of Frontal Fibrosing Alopecia
- Bitemporal alopecia areata
- Skin transcriptome reveals the Periodic changes in genes underlying hair follicle cycling in Cashmere goats
- Pharmacological Treatment of Alopecia
- British Hair and Nail Society
- Trichodystrophies: A hair-raising differential diagnosis
- Chemotherapy and Cutaneous Drug Reactions
- Compounding as a Current Therapeutic Option in Dermatology
- Diagnostic challenges in determining alopecia areata
- Reassessing frontal fibrosing alopecia
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation
- DERMATOLOGICAL AND SYSTEMIC REACTIONS TO HAIR DYES: CURRENT EVIDENCE AND MANAGEMENT
- Lipid nanocarriers as innovative strategies for hair regrowth
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Case Report: Compound heterozygous variants in LSS and TSPEAR genes causing hypotrichosis type 14 complicated with ectodermal dysplasia type 14
- Familial Pure Hair–Nail Ectodermal Dysplasia in Yemen: A Father–Son Case Report with Clinical Correlation
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata